Shares of cancer treatment company Juno Therapeutics Inc. are surging 60 percent in their stock market debut.
Juno genetically engineers a patient's own white blood cells to find and kill cancer cells in the body. It says its clinical trials have shown evidence of tumors shrinking.
Continue Reading Below
The Seattle-based company raised $264.5 million after selling more than 11 million shares at $24 per share. It plans to use the cash raised to continue trials and studies. The stock is listed on the Nasdaq stock market under ticker symbol "JUNO."
The stock is up $14.33 to $38.33 in morning trading.